News | Embolic Protection Devices | July 20, 2018

Boston Scientific to Acquire TAVR Embolic Protection Company Claret Medical

Addition of FDA-cleared Sentinel Cerebral Embolic Protection System will expand Boston's structural heart offerings

Claret's FDA-cleared Sentinel Cerebral Embolic Protection System for TAVR will expand Boston Scientific's structural heart portfolio. It collects emboli knocked loose that would otherwise lodge in the brain and potentially cause a stroke.

Claret's FDA-cleared Sentinel Cerebral Embolic Protection System for TAVR will expand Boston Scientific's structural heart portfolio. It collects emboli knocked loose that would otherwise lodge in the brain and potentially cause a stroke. 

Claret's FDA-cleared Sentinel Cerebral Embolic Protection System for TAVR will expand Boston Scientific's structural heart portfolio. It collects emboli knocked loose that would otherwise lodge in the brain and potentially cause a stroke.

Claret's FDA-cleared Sentinel Cerebral Embolic Protection System for TAVR will expand Boston Scientific's structural heart portfolio. It collects emboli knocked loose that would otherwise lodge in the brain and potentially cause a stroke. 

July 20, 2018 — Boston Scientific Corp. today has signed an agreement to acquire Claret Medical Inc., which has commercialized an embolic protection filter to reduce the risk of strokes during transcatheter aortic valve replacement (TAVR) procedures. The purchase price was $220 million in up-front cash, as well as a potential reimbursement-based milestone payment of up to $50 million.

The privately held company developed and commercialized the Sentinel Cerebral Embolic Protection System. The device is used to protect the brain during certain interventional procedures, predominately in patients undergoing TAVR. The technology will expand Boston Scientific's structural heart portfolio, which includes the Watchman left atrial appendage ocular and the Lotus TAVR valve. 

The Sentinel System received European CE mark in 2014 and U.S. Food and Drug Administration (FDA) clearance in 2017. It is the only device cleared to protect patients against the risk of stroke during TAVR, a minimally invasive procedure to replace the aortic valve in patients with severe aortic stenosis. Embolic debris such as calcium or tissue can embolism during the procedure, travel through the bloodstream toward the brain and potentially cause neurological and neurocognitive damage. Recent studies have estimated about 4 percent of patients experience a clinically apparent stroke within 30 days of a TAVR procedure.[1,2,3,4,5,6]

"Through the development and commercialization of the Sentinel System, Claret Medical has successfully introduced a new layer of safety and peace of mind for physicians and their patients undergoing TAVR procedures," said Kevin Ballinger, president, interventional cardiology, Boston Scientific. "This acquisition will expand our commercial portfolio to include an important adjunctive offering aimed at improving TAVR patient outcomes. We also see potential for future use in other left heart and endovascular procedures such as mitral valve repair and replacement, left atrial appendage closure and pulmonary vein isolation ablation procedures for atrial fibrillation."

 

Trial Evidence Supporting the Sentinel Device

In the pivotal SENTINEL Trial, the landmark study that led to FDA clearance and commercial introduction of this first-time therapy in the U.S., the Sentinel System reduced the incidence of strokes by 63 percent within the first 72 hours of the procedure.[7] In clinical studies, the Sentinel System captured debris flowing toward the brain in 99 percent of TAVR cases, regardless of the type of replacement valve that was used.[8]

"We have been pleased by the consistent, high-quality clinical evidence generated by the committed thought leaders at leading academic centers, as well as the rapid physician adoption of the device — utilized on average in 60 percent of TAVR procedures performed across 100 centers – within just 12 months of carefully controlled U.S. commercialization," said Azin Parhizgar, Ph.D., president and chief executive officer, Claret Medical. "Nearly 10,000 patients have been treated worldwide with the Sentinel System, and we are confident that the leadership of Boston Scientific will enable increased momentum and improved patient access to this valuable technology."

Claret Medical is based in Santa Rosa, Calif., and has about 120 employees. The acquisition is projected to close during the third quarter of 2018, subject to customary closing conditions.

The transaction is expected to be immaterial to adjusted earnings per share in 2018, accretive in 2019 and increasingly accretive thereafter. On a GAAP basis, the transaction is expected to be less accretive, or more dilutive as the case may be, due to amortization expense and acquisition-related net charges.

 

Related Content on the Sentinel Embolic Protection System

TAVR Embolic Protection Systems to Reduce Stroke Rates

Sentinel Cerebral Protection System Reduces TAVR Strokes More Than 60 Percent

Sentinel Cerebral Protection System Reaches 50-Center Adoption Milestone in U.S.

Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR

PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System

FDA Clears First TAVR Embolic Protection System

TCT 2014: Editor's Choice of the Most Innovative New Technologies
 

References:

1. Martin B Leon, et al., Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. N Engl J Med. 2010;363:1597-1607.

2. John Webb, et al. A Randomized Evaluation of the SAPIEN XT Transcatheter Heart Valve System in Patients With Aortic Stenosis Who Are Not Candidates for Surgery. J Am Coll Cardiol Intv. 2015;8:1797-1806.

3. Craig Smith, et al. Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients. N Engl J Med. 2011;364:2187-98. 

4. Martin B Leon, et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med 2016;374:1609-20. 

5. Jeffrey Popma, et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol 2014;63:1972-81. 

6. David H Adams, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 2014;370:1790-98.

7. Samir Kapadia S, et al. Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement. JACC. Jan 2017; 69(4): 367-377. 
 
8.
Tobias Schmidt T, et al. Debris Heterogeneity Across Different Valve Types Captured by a Cerebral Protection System During Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions. Jul 2018; 11(13): 1262-1273.

Related Content

Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
Videos | Cath Lab | September 14, 2018
A discussion with Nicolas Bevins, Ph.D., vice chair, physics and research, and Jessica Harrington, RCIS.
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Overlay Init